ClinicalTrials.gg
RecruitingNCT06130449Updated Oct 6, 2026

Testosterone and Neural Function in Men With Spinal Cord Injury

An Early Phase 1 interventional study of Natesto testosterone intranasal gel and Ayr Saline Nasal Gel in Spinal Cord Injury, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by VA Office of Research and Development · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Oct 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Spinal Cord Injuries by VA Office of Research and Development — 17 open to participants now, 18 under way, 1 of them phase 3. Spinal Cord Injuries · VA Office of Research and Development.

Planned enrollment
41st of 69
15 · median 20
Started
2024
with 3 others
Phase 1
3 of 76
1 open now
Primary completion
2026-12
later than 1 of 17 live
Registered
68th of 76
by date

Among the 76 studies in Spinal Cord Injuries by VA Office of Research and Development, this one is the 41st largest by planned enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2024, is one of 3 in phase 1, reaches primary completion later than 1 of the 17 other live ones, and was the 68th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

17 of the 76 studies in Spinal Cord Injuries by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 80 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spinal Cord Injuries by VA Office of Research and Development, or all of them as a file.
02

Study summary

Spinal cord injury (SCI) disrupts the nerves controlling movement, along with those that regulate functions like heart rate and blood pressure (known as the autonomic nervous system, or ANS). Testosterone (T) plays a significant role in brain health and ANS reflex function in non-neurologically impaired men. However, little is known about the relationships between T, nerve function, and ANS dysfunction after SCI. Interestingly, up to 60% of men with SCI exhibit persistently low T concentrations, which may worsen nerve and ANS dysfunction. In uninjured eugonadal people (normal physiologic range of serum T concentrations), a single pharmacologic dose of intranasal T has been shown to quickly improve nerve function, but no study has evaluated if T administration alters nerve and ANS function in men with SCI. Herein, the investigators will conduct the first study to test how a single dose of intranasal T impacts motor and ANS function in this population.

Read the detailed description

Spinal cord injury (SCI) disrupts sensorimotor function and corticospinal excitability, resulting in muscle weakness and autonomic nervous system (ANS) dysfunction that detracts from cardiovascular (CV) health. These deficits may be exacerbated by low testosterone (T), which develops in most men during the acute/subacute phases of SCI and persists in 45-60% of men thereafter. Low T (hypogonadism) is associated with multiple health impairments, including reduced lean tissue mass and increased fat mass, systemic inflammation, and risk for CV and neurodegenerative diseases. Moreover, low T is associated with CV ANS dysfunction and impaired cardiovagal (parasympathetic) reflex function following SCI. In men with low T after SCI, restoring T concentrations to the normal (eugonadal) range with T replacement therapy (TRT) improves energy expenditure, body composition, CV function, and markers of cardiometabolic health. Evidence from animal models also demonstrates that T is neuroprotective, upregulates neurotrophic factors, and promotes neuroplasticity and myelin regeneration. However, the neural effects of intranasal TRT are unknown.

T is the most abundant bioactive androgen within the circulation. It exerts direct biological actions by binding androgen receptors (ARs), affecting transcription, as well as non-genomic mechanisms in the brain, spinal cord, heart, and numerous other tissues throughout the body. The majority of circulating T is bound to sex-hormone binding globulin (SHBG) and albumin, with only 1-4% circulating unbound (free T). Free T and albumin-bound T are collectively termed bioavailable T, as SHBG-bound T cannot readily dissociate to engage cellular receptors. In this regard, a high prevalence of men with SCI not only exhibit low total T, but also exhibit a marked reduction in bioavailable T because there is a >10-fold increase in SHBG after SCI, resulting in lower proportions of free and albumin-bound T.

The primary goal of this proposal is to perform a small pilot/feasibility study to assess neurophysiological and cardiovagal responses to a single dose of intranasal TRT in a cohort of these men who exhibit low Total T (\<300 ng/dL), low Free T (\<46 pg/mL), or low bioavailable T (\<110 ng/dL) and hypogonadal signs/symptoms.

Primary Aim: To investigate the acute effects of a single dose of intranasal TRT (11 mg) compared with placebo on CNS excitability and cardiovagal reflex function 30 minutes after administration in 15 male Veterans (10 with chronic SCI and 5 uninjured controls) who have low baseline total T concentrations. CNS excitability will be assessed using hand muscle electromyography (EMG) output determined by recruitment curves evoked by non-invasive single-pulse transcranial magnetic stimulation (TMS) and cervical transcutaneous spinal cord stimulation (TSCS). A cold face challenge (CFC) while measuring beat-to-beat heart rate signals will be used to examine CV ANS reflex function. Because this Exploratory Aim is a pilot/feasibility study, formal hypothesis testing would be premature. However, based on the literature, the investigators expect that elevating circulating concentrations of T into the high normal physiologic range via intranasal TRT will result in improved neural and cardiovagal function for 6-8 hours after the dose.

The results of this pilot study will inform feasibility and identify modifications needed to design a larger eventual trial to evaluate the efficacy and safety of intranasal TRT. Ours will be the first clinical study to collect pilot/feasibility data on an intranasal TRT formulation that has the potential to improve neural function after SCI. This is significant because our results are expected to provide evidence demonstrating the feasibility of a novel intranasal therapeutic strategy in Veterans with SCI.

03

Conditions studied

  • Spinal Cord Injury

Keywords

  • spinal cord injury
  • testosterone
  • cardiovascular
  • neurophysiology
  • central nervous system
  • autonomic
  • motor function
  • electrical stimulation
  • cardiovagal function
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • Hypogonadal (Serum Total T \<300 nanograms per deciliter (ng/dL), Free T \<46 picograms per milliliter (pg/mL), or bioavailable T \<110 ng/dL) with signs/symptoms of hypogonadism
  • Traumatic or non-traumatic spinal cord injury (SCI)
  • Time since injury (TSI) more than 12 months
  • American Spinal Injury Association (ASIA) Injury classification Scale (AIS) A, B, C, or D
  • Stable prescription medication regimen for at least 30 days
  • Not currently receiving pharmacological treatment for hypogonadism
  • Must be able to commit to study requirements of 3 visits within a 30-day period
  • Provide

Exclusion criteria

Exclusion Criteria:

  • Extensive history of seizures
  • Ventilator dependence or patent tracheostomy site
  • History of neurologic disorder other than spinal cord injury (SCI)
  • History of moderate or severe head trauma
  • Currently receiving treatment for hypogonadism
  • History of allergy, , or other significant adverse reaction to testosterone replacement therapy
  • Significant cardiovascular disease or cardiac conduction disease
  • Active psychological disorder
  • Moderate or severe brain injury, stroke, tumor, multiple sclerosis, or abscess
  • Recent history (within 3 months) of substance abuse
  • Pressures sores stage 3 or greater
  • Active infection
  • Frequent severe migraines
  • Recent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a syndrome of sudden rise in systolic pressure greater than 20 mm Hg or diastolic pressure greater than 10 millimeters of mercury (mm Hg), without rise in heart rate, accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, and blurry vision (this will be closely monitored during all screening and testing procedures)
  • History of implanted devices with electromagnetic properties: brain/spine/nerve stimulators, aneurysm clips, ferromagnetic metallic implants in the head (except for inside mouth); cochlear implants; cardiac pacemaker/defibrillator; intracardiac lines; currently increased intracranial pressure; or other to brain or spine stimulation
  • Use of medications that significantly lower seizure threshold, such as amphetamines, neuroleptics, dalfampridine, and bupropion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
15 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participant-blinded (Ayr Saline Gel)

    Drug: Ayr Saline Nasal Gel

  • Active comparator
    Intranasal TRT

    Participant-blinded (11 mg of Natesto)

    Drug: Natesto testosterone intranasal gel

Interventions

  • DrugNatesto testosterone intranasal gel

    A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.

    Also known as: testosterone intranasal gel

  • DrugAyr Saline Nasal Gel

    A single dose of Ayr (one spray per nostril) will be administered to each participant.

    Also known as: Saline Nasal Gel

06

What researchers measure

Primary outcomes

  1. Electromyographic (EMG) responses

    Response to electrical and magnetic stimulation, singly, will be measured via peak-to-peak amplitude (millivolts) in first dorsal interosseous and abductor pollicis brevis muscles.

    Time frame: up to one day

Secondary outcomes

  1. Serum Testosterone

    Serum testosterone will be assessed prior to and after administration of intranasal TRT.

    Time frame: up to one day

  2. Cardiovagal Function (heart rate variability)

    Changes in beat-by-beat heart rate (beats per minute) signals collected using ECG during a cold face challenge (cardiovagal provocation) to determine cardiovagal reflex function. Changes in the high frequency (0.15-0.4 Hz) component will be used as an indication of parasympathetic activity to the heart.

    Time frame: up to one day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 40 non-industry phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 55. This study's planned 32 months is below that.

Counting every sponsor, half of 51 studies reached it within 36 months; a quarter within 24 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2023
First posted
Nov 14, 2023
StartActual
Apr 1, 2024
Primary completionEst.
Dec 31, 2026was Sep 2026
CompletionEst.
Dec 31, 2026was Sep 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Dec 31, 2026
Oct 6, 2026
Study completion
Sep 30, 2026→Dec 31, 2026
Oct 6, 2026
Eligibility
1 inclusion criterion edited, 1 removed; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedHypogonadal (Serum Total T <300 nanograms per deciliter (ng/dL), Free T <46 picograms per milliliter (pg/mL), or bioavailable T <110 ng/dL) with signs/symptoms of hypogonadism
  • RemovedAge 18-80 years
Exclusion criteria
  • EditedHistory of neurologic disorder other than spinal cord injury (SCI)
  • EditedRecent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a syndrome of sudden rise in systolic pressure greater than 20 mm Hg or diastolic pressure greater than 10 millimeters of mercury (mm Hg), without rise in heart rate, accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, and blurry vision (this will be closely monitored during all screening and testing procedures)
Oct 6, 2026
Title
Testosterone and Neural Function in Men With Spinal Cord Injury
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Sep 30, 2026→Dec 31, 2026
    Study completion Sep 30, 2026→Dec 31, 2026
    Eligibility 1 inclusion criterion edited, 1 removed; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedHypogonadal (Serum Total T <300 nanograms per deciliter (ng/dL), Free T <46 picograms per milliliter (pg/mL), or bioavailable T <110 ng/dL) with signs/symptoms of hypogonadism
    • RemovedAge 18-80 years
    Exclusion criteria
    • EditedHistory of neurologic disorder other than spinal cord injury (SCI)
    • EditedRecent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a syndrome of sudden rise in systolic pressure greater than 20 mm Hg or diastolic pressure greater than 10 millimeters of mercury (mm Hg), without rise in heart rate, accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, and blurry vision (this will be closely monitored during all screening and testing procedures)
    Title Testosterone and Neural Function in Men With Spinal Cord Injury
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06130449
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Apr 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 6, 2026

Study contacts

Jacob A Goldsmith, PhD
Contact
Jacob.Goldsmith@va.gov
(718) 584-9000
Noam Y Harel, MD PhD
Contact
Noam.Harel@va.gov
(718) 584-9000 ext. 1742
Jacob A Goldsmith, PhD
principal investigator · James J. Peters Veterans Affairs Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion